Skip to main content
. 2021 Nov 1;40(2):308–313. doi: 10.1007/s10637-021-01179-2

Table 2.

Overview of adverse events and discontinuations

n (%) Anlotinib (n = 8)
Total patients with ≥ 1 AE 8 (100.0)
Serious AE 3 (37.5)
Severe AE (grade ≥ 3) 5 (62.5)
AE leading to death 0 (0.0)
AE leading to withdrawal from treatment 2 (25.0)
AE leading to dose modification/interruption 5 (62.5)
Treatment-related AE 8 (100.0)
Treatment-related serious AE 3 (37.5)